The Holistic Primary Care Webinar Explores the Science and Clinical Applications of Palmitoylethanolamide (PEA)

July 10, 2026 – A recent webinar hosted by Holistic Primary Care delved into the multifaceted therapeutic potential of palmitoylethanolamide (PEA), a naturally occurring lipid mediator, with a particular focus on its advanced formulation, Levagen®+ by Saanroo. The online event, led by distinguished chemist Ramasamy V. Venkatesh, aimed to equip holistic practitioners with in-depth scientific knowledge and clinical evidence to effectively integrate PEA into their patient care strategies, addressing the persistent challenges of chronic pain and inflammation that often limit conventional pharmaceutical interventions.

The webinar, which took place on Friday, July 10, 2026, at 18:42 GMT, was designed to bridge the gap between emerging scientific understanding of endogenous pain regulation and practical clinical application. It underscored the limitations of current pharmaceutical approaches, which frequently present concerns regarding adverse effects, the risk of dependency, and an insufficient capacity to tackle the complex underlying biology of neuroinflammation.

Understanding Palmitoylethanolamide (PEA): An Endogenous Solution to Pain and Inflammation

Palmitoylethanolamide (PEA) is a fatty acid amide that the human body naturally synthesizes. It plays a crucial role in modulating pain perception and facilitating tissue repair. The webinar highlighted PEA’s unique mechanism of action, which involves a multi-receptor signaling pathway. Chemist Ramasamy V. Venkatesh, a recognized authority in the nutraceutical industry, provided a comprehensive overview of these interactions.

According to Venkatesh, PEA primarily exerts its effects through the activation of peroxisome proliferator-activated receptor alpha (PPAR-α). This activation is central to its anti-inflammatory and analgesic properties. Beyond PPAR-α, PEA also indirectly modulates cannabinoid receptors, specifically CB1 and CB2, which are integral components of the body’s endocannabinoid system. Furthermore, its influence extends to interactions with G-protein coupled receptor 55 (GPR55) and transient receptor potential vanilloid 1 (TRPV1) channels. These interactions collectively contribute to PEA’s ability to target pain pathways at both peripheral and central nervous system levels, crucially without inducing the psychoactive effects associated with some cannabinoid compounds. This "parallel endocannabinoid" signaling pathway, as described in the webinar, positions PEA as a distinct and valuable therapeutic agent.

Levagen®+ and LipiSperse® Technology: Enhancing PEA Bioavailability

A significant portion of the webinar was dedicated to Saanroo’s Levagen®+ formulation. The key innovation highlighted is the integration of patented LipiSperse® dispersion technology. This proprietary technology is designed to significantly enhance the absorption and bioavailability of PEA. Conventional PEA formulations can sometimes face challenges with absorption due to its lipophilic nature. LipiSperse® aims to overcome these limitations by improving the dispersion of PEA in the gastrointestinal tract, thereby increasing the amount of active compound available for uptake by the body. This technological advancement is critical for ensuring that patients receive the full therapeutic benefit of PEA.

The webinar emphasized that Levagen®+ is not merely a generic PEA supplement but a clinically validated formulation that leverages advanced delivery systems to optimize its efficacy. This focus on improved bioavailability addresses a common concern in the nutraceutical industry, where the effectiveness of orally administered compounds can be significantly influenced by their absorption rates.

Clinical Evidence Supporting Levagen®+ Efficacy

Dr. Ramasamy V. Venkatesh presented a robust review of the clinical research supporting the efficacy of Levagen®+ across a spectrum of pain and inflammation-related conditions. The presented data included findings from randomized, double-blind, placebo-controlled trials, considered the gold standard in clinical research. These studies demonstrated Levagen®+’s effectiveness in addressing:

• Joint Pain and Stiffness: Clinical trials have indicated significant improvements in pain scores and joint mobility for individuals suffering from osteoarthritis and other degenerative joint conditions. Data suggests a notable reduction in the need for rescue pain medication in participants utilizing Levagen®+.
• Acute Menstrual Pain (Dysmenorrhea): Research presented showed that Levagen®+ can effectively alleviate the severe cramping and discomfort associated with menstruation, offering a non-opioid alternative for pain management. Studies have reported a reduction in the duration and intensity of menstrual pain, as well as a decrease in the use of NSAIDs.
• Migraine: The webinar discussed evidence suggesting PEA’s potential in managing migraine headaches, both in terms of reducing frequency and severity. The anti-inflammatory and neuroprotective mechanisms of PEA are thought to contribute to its benefits in this area.
• Exercise-Induced Muscle Damage (EIMD): For athletes and active individuals, Levagen®+ has shown promise in accelerating recovery from muscle soreness and reducing inflammation post-exercise. Studies have documented faster return to baseline muscle function and reduced levels of markers indicative of muscle damage.

The presentation underscored that the application of Levagen®+ is best understood as a precision tool targeting specific endocannabinoid-adjacent pathways involved in pain and inflammation, rather than a generalized supplement. This nuanced approach allows practitioners to tailor its use to individual patient needs and specific conditions.

Background of the Event and its Significance

The increasing prevalence of chronic pain and inflammatory conditions has placed a significant burden on healthcare systems worldwide. The World Health Organization (WHO) estimates that chronic pain affects up to 20% of the global population, with conditions like osteoarthritis and inflammatory bowel disease seeing rising incidence rates. Simultaneously, the demand for natural and non-addictive therapeutic options is growing among consumers and healthcare providers alike. Holistic primary care practitioners, in particular, are actively seeking evidence-based natural interventions that can complement or offer alternatives to conventional pharmaceutical treatments.

This webinar by Holistic Primary Care and sponsored by Saanroo represents a timely effort to disseminate crucial information about PEA and its advanced formulations. By focusing on a well-researched endogenous compound and a scientifically validated delivery system, the event aims to empower practitioners with the knowledge to confidently incorporate PEA into their treatment protocols. The choice of July 10, 2026, for the webinar suggests a strategic placement to inform practitioners ahead of potential upcoming product launches or as part of ongoing educational initiatives within the industry.

Expert Insights from Ramasamy V. Venkatesh

Ramasamy V. Venkatesh, the featured speaker, brings over four decades of experience in the pharmaceutical and nutraceutical industries. As the founder and managing director of the Gencor Group worldwide, he possesses extensive international business acumen, having operated in over 70 countries. His expertise spans R&D management, scientific reviews, product development, clinical trials, branding, and strategic partnerships. Venkatesh has a proven track record of successfully launching branded products in the global nutraceutical market. His contributions were recognized in 2024 with the Nutri Champion Award from NutraIngredients, acknowledging the significant impact of his work on the dietary supplement industry. He is widely respected for his commitment to raising industry standards through the use of high-quality, clinically supported ingredients.

Beyond his professional achievements, Venkatesh is known for his exceptional work ethic and dedication. The webinar highlighted his commitment to promoting equal opportunities and empowering women in business and sports, showcasing a holistic approach that extends beyond scientific and commercial pursuits. His extensive background and recognition within the industry lend significant credibility to the information presented regarding PEA and Levagen®+.

Implications for Holistic Healthcare Practice

The implications of this webinar for holistic primary care practitioners are substantial. By providing a deep dive into the scientific rationale and clinical evidence for PEA, especially in its enhanced Levagen®+ formulation, the event equips them with a powerful new tool.

• Expanded Treatment Options: Practitioners can now confidently offer PEA as a targeted intervention for a wider range of pain and inflammation-related conditions, potentially reducing reliance on NSAIDs or opioids, which carry significant risks.
• Patient-Centric Care: The focus on PEA as a precision tool encourages a more personalized approach to patient care, allowing practitioners to address the specific underlying mechanisms of pain and inflammation.
• Evidence-Based Integration: The emphasis on randomized, double-blind, placebo-controlled trials ensures that practitioners are integrating evidence-based interventions into their practice, enhancing patient outcomes and professional credibility.
• Addressing Unmet Needs: For patients who have not responded adequately to conventional treatments or are seeking natural alternatives, PEA offers a promising new avenue for relief.

The webinar’s success in disseminating this information suggests a growing interest in endogenous compounds and advanced delivery systems within the holistic health community. As research into PEA continues to evolve, practitioners who attended this session are well-positioned to remain at the forefront of innovative pain and inflammation management.

Future Outlook and Research Directions

The discussion around PEA, particularly with advanced formulations like Levagen®+ powered by LipiSperse® technology, points towards a future where endogenous compounds are increasingly leveraged for therapeutic benefits. Continued research is likely to explore PEA’s role in other inflammatory conditions, neurodegenerative diseases, and its synergistic effects with other natural compounds. The focus on bioavailability and targeted delivery mechanisms will remain a critical area of development, ensuring that the therapeutic potential of such compounds can be fully realized.

The event sponsored by Saanroo underscores the company’s commitment to advancing the science and accessibility of well-researched ingredients. As the scientific community and the public continue to seek safer and more effective solutions for chronic pain and inflammation, PEA stands out as a compelling option, supported by rigorous scientific investigation and innovative formulation technology.